May 16, 2024 / 08:00AM GMT
Magnus Corfitzen - Ascelia Pharma AB - Chief Executive Officer
Thank you, and welcome, everyone, to the Q1 report for 2024. On this call, we will be making forward-looking statements. On today's call, we will start with the significant highlights and recent key events. This will be followed by a portfolio update before moving to financials and priorities ahead. As mentioned, after the presentation, we will open up for questions.
At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglance has now been advanced to the registration phase as we have successfully completed the pivotal Phase 3 clinical study. Orviglance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million.
Oncoral is ready to start Phase 2 in the treatment of gastric cancer based on encouraging results in Phase 1 and a high level of unmet medical need. We are based in Norway and Sweden and are listed on Nasdaq Stockholm since 2019.
In Q1, we
Q1 2024 Ascelia Pharma AB Earnings Call Transcript
May 17, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers